Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-low and HER2-ultralow metastatic breast cancer, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Immunohistochemistry was never designed to score low expression and pathologists disagree at the 0 to 1+ boundary.
Whether a second topoisomerase I payload works after the first.
Interstitial lung disease remains unpredictable.
The triple-negative HER2-low group has only exploratory randomised data.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
OS 23.
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS HR 0.